| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1847.7 | 1876.3 | 1769.6 |
| Other income | 25.5 | 15.5 | 14.2 |
| Total income | 1873.2 | 1891.8 | 1783.8 |
| Profit before exceptional items & tax | 143.4 | 203.7 | 191.9 |
| Exceptional items | -24.8 | -42.2 | 0.0 |
| Profit before tax | 118.6 | 161.5 | 191.9 |
| Net profit | 201.5 | 131.9 | 156.6 |
| Operating margin | 6.3% | 8.5% | 10.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +28.70% |
|---|---|
| Net profit, quarter on quarter | +52.80% |
| Revenue, year on year | +4.40% |
BSE results filing, NSE: APLLTD. Figures extracted from the filing.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹863.75
- Market cap
- ₹16,978 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 24.5×Sector 50.4×
- Promoter holding
- 69.87%+0.13% QoQ
- FII holding
- 4.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Debt & Borrowing: ₹100 Cr
Alembic Pharmaceuticals Limited has redeemed Commercial Papers (CP) worth Rs. 100 Crores. The redemption was completed on the maturity date of September 25, 2026.
- Value
- ₹100.0 Cr
Alembic Pharmaceuticals Debt & Borrowing: ₹150 Cr
Alembic Pharmaceuticals has redeemed Commercial Papers worth Rs. 150 Crore upon maturity on 23rd September 2026.
- Value
- ₹150.0 Cr
Alembic Pharmaceuticals Debt & Borrowing: ₹150 Cr
Alembic Pharmaceuticals has successfully redeemed Commercial Papers worth ₹150 Crore upon maturity. This confirms the repayment of the company's debt obligation.
- Value
- ₹150.0 Cr
Alembic Pharmaceuticals Business Update
Alembic Pharmaceuticals completed an unannounced USFDA onsite inspection at its Vadodara Bioequivalence Facility. The inspection concluded with zero Form 483 observations, a positive regulatory signal.
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.26 Cr
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in the UAE for Rs. 0.26 Crore to explore new business opportunities in pharmaceuticals.
- Value
- ₹0.26 Cr
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.25 Cr
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai to explore new business opportunities and distribution.
- Value
- ₹0.25 Cr